Notch Mutations as a Novel Biomarker for Immunotherapy

Kei Kunimasa¹

Affiliations

PMID: 37087125
DOI: 10.1016/j.jtho.2023.01.087

Free article

Comment

Notch Mutations as a Novel Biomarker for Immunotherapy

Kei Kunimasa. J Thorac Oncol. 2023 May.

Free article

. 2023 May;18(5):e53-e54.

doi: 10.1016/j.jtho.2023.01.087.

Author

Kei Kunimasa¹

Affiliation

¹ Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan. Electronic address: keikunimasa@gmail.com.

PMID: 37087125
DOI: 10.1016/j.jtho.2023.01.087

No abstract available

PubMed Disclaimer

Comment in

Notch Mutations as a Novel Biomarker for Immunotherapy.
Zhou F, Zhou C. Zhou F, et al. J Thorac Oncol. 2023 May;18(5):e54-e56. doi: 10.1016/j.jtho.2023.02.014. J Thorac Oncol. 2023. PMID: 37087126 No abstract available.

Comment on

Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial.
Zhou C, Huang D, Fan Y, Yu X, Liu Y, Shu Y, Ma Z, Wang Z, Cheng Y, Wang J, Hu S, Liu Z, Poddubskaya E, Disel U, Akopov A, Dvorkin M, Zheng W, Ma Y, Wang Y, Li S, Yu C, Rivalland G. Zhou C, et al. J Thorac Oncol. 2023 Jan;18(1):93-105. doi: 10.1016/j.jtho.2022.09.217. Epub 2022 Sep 29. J Thorac Oncol. 2023. PMID: 36184068 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Notch Mutations as a Novel Biomarker for Immunotherapy

Affiliation

Notch Mutations as a Novel Biomarker for Immunotherapy

Author

Affiliation

Comment in

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical